Research explained
Sermorelin vs Tesamorelin: Evidence & Differences
Compare sermorelin and tesamorelin by studied population, clinical endpoints and regulatory history, with primary sources and clear limits on fat-loss claims.
By PurePeptideHub Research Team · Evidence updated
Editorial evidence update; independent clinical review pending. Editorial standards
These compounds are not interchangeable. The evidence below does not establish a winner for general weight loss or anti-aging.
Evidence at a glance
Selected sources supporting this update. This is an editorial evidence summary, not a systematic review of every publication.
| Source and design | What it supports | What it cannot establish |
|---|---|---|
| FDA: why GEREF was discontinued 2013 regulatory determination | FDA found that the discontinued GEREF products were not withdrawn for safety or effectiveness reasons. | This historical finding is not approval of a current compounded product or a new indication. |
| GEREF International Study Group, 1996 Clinical study in children with growth hormone deficiency | Investigators studied growth response to GHRH treatment in a pediatric population. | Pediatric growth outcomes cannot establish adult fat-loss, recovery or longevity benefits. |
| EGRIFTA WR: current prescribing information US product labeling | Tesamorelin has an indication for excess abdominal fat in adults with HIV-associated lipodystrophy; it is not indicated for weight-loss management. | The indication is specific to a population and formulation, not all fat-loss goals or products. |
What is the main difference?
Both belong to the growth hormone-releasing hormone family, but a shared pathway does not mean a shared clinical purpose. The useful comparison is the actual product, population and outcome being discussed. A change in a hormone concentration is a different endpoint from a change in symptoms, body weight or health.
Sermorelin: put the historical evidence in context
The pediatric study and FDA notice answer separate questions: what was investigated, and why a branded product left the market. Neither source establishes an adult wellness protocol. When a seller uses the historical brand name to support a different formulation or use, ask for the evidence connecting the two.
Tesamorelin: abdominal fat is not the same endpoint as weight loss
Its labeled use concerns a particular fat distribution problem in people with HIV. The label also discusses glucose intolerance, raised IGF-1, fluid retention and contraindications. These details matter more than a headline promising general fat loss. The current product information is linked above so readers can check its full scope.
Is there a head-to-head winner?
The selected sources do not directly compare sermorelin with tesamorelin for the same endpoint in the same population. Cross-trial comparisons can be misleading when eligibility, formulation, duration and outcome measures differ. We cannot rank them for your health goals from this evidence.
How to evaluate a comparison claim
Check whether the citation actually names the compound and formulation in the claim. Then identify the study population, comparison group, measured outcome and follow-up. For personal treatment decisions, those details belong in a discussion with a qualified clinician, alongside the actual prescribing information.
Common questions
Is tesamorelin better than sermorelin for weight loss?
These sources do not establish that comparison. Weight change, visceral fat and hormone concentrations are different outcomes; evidence for one cannot be relabeled as evidence for another.
Was sermorelin discontinued because it was unsafe?
The cited FDA determination says safety or effectiveness was not the reason for the GEREF withdrawals. It does not validate every product now marketed as sermorelin.
Can I use a sermorelin dose for tesamorelin?
No dose equivalence is established here. Do not transfer a dose or preparation method between different compounds or formulations.
Continue your research
Educational information only. This page does not recommend a medicine, dose or injection protocol. Report a correction with its source.